These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 1922654

  • 21. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
    Zhang J, Wang X, Lu H.
    Cancer Lett; 2008 Feb 18; 260(1-2):127-36. PubMed ID: 18039557
    [Abstract] [Full Text] [Related]

  • 22. Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.
    Lee CK, Park KK, Hwang JK, Lee SK, Chung WY.
    Phytother Res; 2009 Jul 18; 23(7):999-1005. PubMed ID: 19140122
    [Abstract] [Full Text] [Related]

  • 23. Newer insights into cisplatin nephrotoxicity.
    Anand AJ, Bashey B.
    Ann Pharmacother; 1993 Dec 18; 27(12):1519-25. PubMed ID: 8305788
    [Abstract] [Full Text] [Related]

  • 24. [Effect of sodium thiosulfate on the antitumor effect and nephrotoxicity of CDDP in human gastric cancer transplanted in nude mice].
    Saito D, Fujii T, Yoshida S, Ohkura H, Oguro Y.
    Gan To Kagaku Ryoho; 1989 Mar 18; 16(3 Pt 1):379-85. PubMed ID: 2930203
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Lipid peroxides and antioxidant enzymes in cisplatin-induced chronic nephrotoxicity in rats.
    González R, Romay C, Borrego A, Hernández F, Merino N, Zamora Z, Rojas E.
    Mediators Inflamm; 2005 Aug 14; 2005(3):139-43. PubMed ID: 16106099
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
    Kubota A, Yoshida T, Tsukuda M, Furukawa S, Miyata K, Mochimatsu I, Sawaki S.
    Gan To Kagaku Ryoho; 1989 Aug 14; 16(8 Pt 1):2599-605. PubMed ID: 2774590
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Phase I and II agents in cancer therapy: two cisplatin analogues and high-dose cisplatin in hypertonic saline or with thiosulfate protection.
    Fuks JZ, Wadler S, Wiernik PH.
    J Clin Pharmacol; 1987 Aug 14; 27(5):357-65. PubMed ID: 3320104
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A comparison of the rates of cisplatin (cDDP)--induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure.
    Leu L, Baribeault D.
    J Oncol Pharm Pract; 2010 Sep 14; 16(3):167-71. PubMed ID: 19759050
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.